On September 9, 2020 TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, reported that the Company’s President Mr. George Yeh and Chief Medical Officer Dr. George Spencer-Green, MD, will be presenting at HC Wainwright & Co’s 22nd Annual Global Investment Conference on Monday, September 14, 2020, at 10:00am ET (Press release, Taiwan Liposome Company, SEP 9, 2020, https://tlcbio.gcs-web.com/news-releases/news-release-details/tlc-present-hc-wainwright-co-22nd-annual-global-investment [SID1234564833]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The 20-minute live presentation will include a company overview and update by Mr. Yeh, with analyses of data on TLC’s pain programs – TLC599 and TLC590 – by Dr. Spencer-Green. During the virtual conference, which will take place September 14-16, 2020, TLC will also be participating in one-on-one sessions.

The corporate slide deck used during the live presentation will be available on the company’s website at www.tlcbio.com in the Investors section, under News & Events.